Sangamo Therapeutics

508 articles with Sangamo Therapeutics

• Sangamo Therapeutics Reports Second Quarter 2019 Financial Results

  8/7/2019

  Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported second quarter 2019 financial results and recent business highlights.

• Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences - Aug. 6, 2019

  8/6/2019

  Sangamo Therapeutics, Inc., a genomic medicine company, announced that CEO Sandy Macrae will present at the 2019 Wedbush PacGrow Healthcare Conference in New York City.

• Sangamo Therapeutics Appoints Gary H. Loeb as Executive Vice President and General Counsel

  7/31/2019

  Sangamo Therapeutics, Inc., a genomic medicine company, announced the appointment of Gary H. Loeb as Executive Vice President and General Counsel, effective immediately.

• Sangamo Therapeutics Announces Second Quarter 2019 Conference Call and Webcast

  7/31/2019

  Sangamo Therapeutics, Inc., a genomic medicine company, announced that the Company will release its second quarter 2019 financial results after the market closes on Wednesday, August 7, 2019.

• Sangamo Announces Nature Biotechnology Publication of New Strategies for Optimizing the Specificity of Gene Editing Nucleases

  7/29/2019

  Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the publication in Nature Biotechnology of a manuscript by Jeffrey Miller, Ph.D., and colleagues at Sangamo, describing two new strategies for optimizing the specificity of genome editing using zinc finger nucleases (ZFNs)

• Sangamo and Pfizer Announce Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained Increased Factor VIII Levels

  7/6/2019

  Sangamo Therapeutics, Inc. and Pfizer, Inc. announced updated results from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy for severe hemophilia A.

•  Sangamo Therapeutics Announces Nature Medicine Publication Detailing the Activity of Disease Allele-Selective Zinc Finger Proteins in Preclinical Models of Huntington’s Disease

  7/1/2019

  Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the publication of a manuscript describing the activity of allele-selective zinc finger protein transcription-factors (ZFP-TFs) in preclinical models of Huntington’s disease (HD).

• Sangamo Announces Upcoming Presentation Of Investigational SB-525 Hemophilia A Gene Therapy Data At ISTH 2019

  6/21/2019

  Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced the upcoming presentation of data from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy in patients with severe hemophilia A

• 

  More Hacks Inevitable in Pharma Industry, Cybersecurity Expert Says

  5/22/2019

  Andrew Douthwaite, chief technology officer for Colorado-based VirtualArmour, a cybersecurity company, told BioSpace that biotech and pharma companies are desirable targets for hackers and cyber thieves due to the value of the intellectual property.

• Sangamo Therapeutics Announces Presentations At Upcoming Scientific, Medical And Investor Conferences

  5/15/2019

  Hemophilia A SB-525 gene therapy clinical data accepted for oral presentation at ISTH

• Sangamo Therapeutics Announces Participation In The Bank Of America Merrill Lynch 2019 Health Care Conference

  5/10/2019

  Sangamo Therapeutics, Inc. (NASDAQ: SGMO) announced today that Sangamo will participate in the Bank of America Merrill Lynch 2019 Health Care Conference being held next week in Las Vegas

• Sangamo Therapeutics Reports First Quarter 2019 Financial Results

  5/8/2019

  Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported first quarter 2019 financial results and recent business highlights.

• Sangamo Therapeutics Announces First Quarter 2019 Conference Call And Webcast

  5/1/2019

  Sangamo Therapeutics, Inc. announced that the Company will release its first quarter 2019 financial results after the market closes on Wednesday, May 8, 2019.

• Sangamo Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares - April 8, 2019

  4/8/2019

  Sangamo Therapeutics, Inc. announced the completion of its previously announced underwritten public offering of 12,650,000 shares of its common stock at a price to the public of $11.50 per share, including 1,650,000 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares.

• Sangamo Therapeutics Announces Pricing of Public Offering of Common Stock

  4/4/2019

  Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $11.50 per share.

• Sangamo Therapeutics Announces Proposed Public Offering of Common Stock

  4/3/2019

  Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced that it has commenced an underwritten public offering of shares of its common stock.

• 

  Sangamo Jumps 28 Percent on Positive Early Hemophilia Trial Data

  4/3/2019

  The California-based company also shared positive early data from a beta thalassemia study and announced plans to increase AAV manufacturing.

• Sangamo Provides Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-edited Cell Therapy Data

  4/2/2019

  Conference call and webcast scheduled for 8:00 a.m. Eastern Time

• Sangamo Announces Agreement Securing Access To Large-Scale, Commercial-Grade Manufacturing Capacity At Brammer Bio

  4/2/2019

  Balanced in-house and contract manufacturing strategy to provide clinical and commercial supply for Sangamo's growing pipeline of AAV-based genomic therapies

• Sangamo and Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy

  4/2/2019

  Eight patients treated with SB-525 gene therapy showed dose-dependent increases in FVIII activity, with the two patients treated with the 3e13 vg/kg dose reaching normal FVIII levels